Meeting
2022 ASCO Annual Meeting
Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor in patients with locally advanced or metastatic breast cancer: Initial results from a phase II study.
Authors
Tamta Makharadze
LTD High Technology Hospital Medcenter, Batumi, Georgia
Tamta Makharadze , Ivane Kiladze , Giorgi Dzagnidze , Nino Semionova , Lika Katselashvili , Natia Vekua , Kasi V. Routhu , Prajak J. Barde , Ajit Nair
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT05021900
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1059)
DOI
10.1200/JCO.2022.40.16_suppl.1059
Abstract #
1059
Poster Bd #
437
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor, in patients with locally advanced or metastatic breast cancer: Updated results from an on-going phase II study.
First Author: Tamta Makharadze
Poster
2024 ASCO Breakthrough
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.
First Author: Joohyuk Sohn
Poster
2019 ASCO Annual Meeting
Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.
First Author: Geoffrey J Lindeman
Poster
2023 ASCO Annual Meeting
LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.
First Author: Binghe Xu